Eisai and Biogen Launch Weekly Subcutaneous Injection for Early Alzheimer’s Treatment

Eisai Co., Ltd. and Biogen Inc. have announced the U.S. availability of LEQEMBI IQLIK, a once-weekly subcutaneous injection for initiating therapy in adults with early Alzheimer's disease (AD). This new treatment option offers an alternative to intravenous (IV) dosing, enhancing convenience and flexibility for patients with mild cognitive impairment or mild dementia due to AD. LEQEMBI IQLIK is administered through […]

NewsBeagle is a discovery engine. We show the headline, a short source-supplied summary and clear attribution. The complete reporting remains with the publisher.